Revance Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2014 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Revance Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2014 to Q3 2024.
  • Revance Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -458 %, a 81.8% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -458 +2.06K +81.8% Sep 30, 2024
Q2 2024 -514 -1.95K -136% Jun 30, 2024
Q1 2024 -742 -2.5K -142% Mar 31, 2024
Q4 2023 -937 -2.21K -173% Dec 31, 2023
Q3 2023 -2.52K -3.45K -370% Sep 30, 2023
Q2 2023 1.44K +445 +44.8% Jun 30, 2023
Q1 2023 1.76K +1.27K +254% Mar 31, 2023
Q4 2022 1.28K +984 +337% Dec 31, 2022
Q3 2022 931 +748 +408% Sep 30, 2022
Q2 2022 994 +861 +645% Jun 30, 2022
Q1 2022 498 +382 +332% Mar 31, 2022
Q4 2021 292 +194 +197% Dec 31, 2021
Q3 2021 183 +92 +101% Sep 30, 2021
Q2 2021 133 +44.8 +50.5% Jun 30, 2021
Q1 2021 115 +44.2 +62.1% Mar 31, 2021
Q4 2020 98.4 +42.4 +75.8% Dec 31, 2020
Q3 2020 91.1 +33.7 +58.6% Sep 30, 2020
Q2 2020 88.7 +42.2 +91% Jun 30, 2020
Q1 2020 71.1 +33.6 +89.7% Mar 31, 2020
Q4 2019 56 +26.4 +89.1% Dec 31, 2019
Q3 2019 57.5 +37.9 +194% Sep 30, 2019
Q2 2019 46.4 +28.8 +163% Jun 30, 2019
Q1 2019 37.5 +21.4 +133% Mar 31, 2019
Q4 2018 29.6 +14.6 +97.1% Dec 31, 2018
Q3 2018 19.5 +2.35 +13.7% Sep 30, 2018
Q2 2018 17.7 +2.03 +13% Jun 30, 2018
Q1 2018 16.1 +2.43 +17.8% Mar 31, 2018
Q4 2017 15 +3.35 +28.7% Dec 31, 2017
Q3 2017 17.2 +7.01 +69% Sep 30, 2017
Q2 2017 15.6 +5.12 +48.7% Jun 30, 2017
Q1 2017 13.7 +2.1 +18.2% Mar 31, 2017
Q4 2016 11.7 +0.31 +2.73% Dec 31, 2016
Q3 2016 10.2 -1.55 -13.2% Sep 30, 2016
Q2 2016 10.5 -0.1 -0.94% Jun 30, 2016
Q1 2016 11.6 +1.34 +13.1% Mar 31, 2016
Q4 2015 11.4 -2.7 -19.2% Dec 31, 2015
Q3 2015 11.7 -30.6 -72.3% Sep 30, 2015
Q2 2015 10.6 Jun 30, 2015
Q1 2015 10.2 Mar 31, 2015
Q4 2014 14.1 Dec 31, 2014
Q3 2014 42.4 Sep 30, 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.